Clinical trial NCT01489969 (phase 2, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: neu-p11
SMILES: COC1=CC=C2NC=C(CCNC(=O)C3=CC(=O)C=CO3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female and aged 18-80 years (both ages included).

          2. Suffering from primary insomnia according to DSM-IV criteria (307.42 primary insomnia,
             Appendix 25.1) (based on a Sleep History Questionnaire (SHQ) that is given to the
             patient at Visit Day 0, Appendix 25.1).

          3. Reported subjective sleep latency of at least 30 minutes on at least three nights per
             week for at least one month and subjective WASO of at least 45 minutes per night on at
             least 3 nights per week for at least one month (based on the SHQ).

          4. Subjects with habitual bed time within the range of 21:00-01:00 (inclusive), as
             reported by the subject during screening on Day 0.

          5. If female of childbearing potential, using a reliable method of contraception during
             the entire study duration and for at least 3 months after study drug intake.

          6. Have not been using benzodiazepine (BZD) and non-BZD hypnotics or melatoninergic drugs
             for the past 2 weeks or more prior to Screening.

          7. Have not been using psychotropic treatments for the past 3 months or more prior to
             Screening.

          8. Are stabilized on non-psychotropic treatments for more than 3 months prior to
             Screening.

          9. Are willing to sign a written informed consent to participate in the study.

             • After initial screening, recruited patients will enter a 2 week placebo
             baseline/eligibility period.

             Patients will be admitted into a sleep lab and will continue to the double blind
             treatment phase if polysomnography (PSG) results meet the following criteria:

         10. Mean LPS ≥30 minutes on both PSG screening nights, with neither night <15 minutes.

         11. Mean total sleep time (TST) ≤390 minutes, or mean WASO ≥30 minutes on both of the 2
             PSG screening nights, with neither night <15 minutes.

        Exclusion Criteria:

          1. According to DSM IV, subjects belonging to the following groups are excluded: 780.59
             (breathing related sleep disorder); 307.45 (circadian rhythm sleep disorder); 307.47
             (dyssomnia not otherwise specified); 780.xx (sleep disorder due to general medical
             condition)

          2. Subjects suffering from insomnia secondary to other causes according to the sleep
             history questionnaire.

          3. Subjects with sleep disorders detected during PSG inclusion/habituation night, such as
             sleep apnea/hypopnea and periodic leg movement syndrome (with arousal) (PLMAI>10
             and/or AHI > 10 per hour).

          4. Use of psychotropic treatments for the past 3 months and during the study.

          5. Use of strong CYP inhibitors in the preceding 3 months and during the study

          6. Use of benzodiazepines or other hypnotics during preceding two weeks (including all
             benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and
             hydroxyzine).

          7. Alcohol intake - no more than 2 alcoholic drinks per day and any consumption less than
             2 hours before study drug intake.

          8. Immunosuppressive medication in the preceding 3 months and during the study

          9. Severe neurological, psychiatric disorders especially psychosis, anxiety and
             depression

         10. Intercurrent acute or chronic somatic diseases likely to interact with sleep (for
             example: chronic pain from any etiology, benign prostatic hypertrophy likely to
             require surgery in the coming six months)